Eli Lilly and Company (LLY) Opens a New Lilly Gateway Labs Innovation Hub in San Diego

With a strong profitability outlook, Eli Lilly and Company (NYSE:LLY) secures a spot on our list of the 14 Stocks That Will Double in the Next 5 Years.

On September 26, 2025, Eli Lilly and Company (NYSE:LLY) opened a new Lilly Gateway Labs innovation hub in San Diego, expanding its global network of facilities supporting early-stage biotech startups. The 82,514-square-foot site can house up to 15 life sciences companies and more than 250 employees, joining existing hubs in Boston, Beijing, and South San Francisco.

As part of Lilly Catalyze360, the program accelerates drug discovery by providing lab space, strategic direction, and scientific collaboration. This expansion underscores Lilly’s industry-leading 83% gross profit margin and $641.5 billion market capitalization, reinforcing its biotech leadership. It also follows recent FDA approval of Inluriyo and plans for a $6.5 billion manufacturing plant in Houston.

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals worldwide, with operations in the U.S., Europe, China, and Japan, and partnerships with firms including Incyte Corporation and Boehringer Ingelheim Pharmaceuticals. It is one of the Stocks That Will Double.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.